Bio-Techne insider exits 17,040 shares after exercising options at $21.84
Rhea-AI Filing Summary
Robert V. Baumgartner, a director of Bio-Techne Corporation (TECH), reported transactions on 08/25/2025 in which he exercised 17,040 stock options with an exercise price of $21.84 and immediately sold 17,040 common shares at a weighted average price of $56.21 (sales ranged $55.97–$56.34). The Form 4 shows a temporary increase in beneficial ownership to 61,903 shares after the exercise, and a final beneficial ownership of 44,863 shares following the sale. The filing lists outstanding stock options across multiple grant years with strike prices from $21.84 to $128.81 and various expiration dates, and notes one option vests on the earlier of the one-year anniversary of the 10/24/2024 grant or Bio-Techne's 2025 annual meeting. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Baumgartner.
Positive
- Exercise and sale documented: 17,040 options exercised at $21.84 and sold at a weighted average of $56.21.
- Complete disclosure of holdings: Form 4 lists outstanding options by strike and expiration, providing transparency on potential future dilution.
Negative
- Reported beneficial ownership decreased: final beneficial ownership after the transactions was 44,863 shares.
- Sale price disclosed as a weighted average: the filing notes shares were sold at prices ranging from $55.97 to $56.34, with per-price breakdown not provided in the form.
Insights
TL;DR Director exercised options and sold all resulting shares, reducing his reported beneficial ownership to 44,863 shares.
The transactions are routine insider option exercise and sale activity documented on Form 4. The exercise price of $21.84 compared with a weighted sale price of $56.21 shows the director realized intrinsic value per share equal to the spread between those prices. The filing also details the director's remaining option portfolio by strike and expiration, which may affect future dilution timing but no dilution occurred in this reported transaction because exercised shares were sold into the market. This disclosure is material for tracking insider liquidity and current reported holdings but contains no operational or financial results for the company.
TL;DR Insider exercised vested options and sold shares; disclosure follows Section 16 reporting requirements.
The Form 4 provides required transparency on beneficial ownership changes: exercise of 17,040 options (exercise price $21.84) and sale of those 17,040 shares (weighted avg $56.21). The report includes a footnote clarifying sale price range and a vesting condition for a recent grant. Filing was executed via power of attorney. There are no indications here of regulatory or governance issues; this is a standard disclosure of option exercise and share disposition by a director.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) | 17,040 | $0.00 | -- |
| Exercise | Common Stock | 17,040 | $21.84 | $372K |
| Sale | Common Stock | 17,040 | $56.21 | $958K |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.97 to $56.34 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders.
